Withdrawn due to non‐compliance with The Cochrane Collaboration’s Commercial Sponsorship Policy The editorial group responsible for this previously published document have withdrawn it from publication.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637244 | PMC |
| http://dx.doi.org/10.1002/14651858.CD008626.pub3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Current Clinical Trials in Traumatic Brain Injury.
Brain Sci
April 2022
Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Traumatic brain injury (TBI) is one of the leading causes of morbidity, disability and mortality across all age groups globally. Currently, only palliative treatments exist, but these are suboptimal and do little to combat the progressive damage to the brain that occurs after a TBI. However, multiple experimental treatments are currently available that target the primary and secondary biochemical and cellular changes that occur after a TBI.
View Article and Find Full Text PDFUpdate on Body Shaping and Volume Restoration: The Role of Hyaluronic Acid.
Aesthetic Plast Surg
August 2020
Akademikliniken, Storängsvägen 10, 115 42, Stockholm, Sweden.
After the introduction of facial aesthetic injectables with botulinum toxin (BoNt) in the first half of the 1990s and nonanimal-based hyaluronic acid (HA) fillers in 1996, the interest for minimally invasive procedures has exploded. With this background, it is not surprising that the interest for body contouring with HA has also attracted a lot of interest. The effectiveness and safety for breast augmentation, buttock augmentation and treatment for pectus excavatum has been extensively investigated and published.
View Article and Find Full Text PDFWITHDRAWN: Optimization of the rat digit abduction score (DAS) assay: Evaluation of botulinum neurotoxin activity in the gastrocnemius lateralis, peronei, and extensor digitorum longus.
Toxicon
February 2020
Ipsen Innovation. 5, Avenue du Canada, 91940 Les Ulis, France.
The Publisher regrets that this article is an accidental duplication of an article that has already been published, https://doi.org/10.1016/j.
View Article and Find Full Text PDFGuideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.
J Headache Pain
September 2018
Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
OnabotulinumtoxinA is being increasingly used in the management of chronic migraine (CM). Treatment with onabotulinumtoxinA poses challenges compared with traditional therapy with orally administered preventatives. The European Headache Federation identified an expert group that was asked to develop the present guideline to provide recommendations for the use of onabotulinumtoxinA in CM.
View Article and Find Full Text PDFReoccurrence of botulinum neurotoxin subtype A3 inducing food-borne botulism, Slovakia, 2015.
Euro Surveill
August 2017
Robert Koch Institute, Consultant laboratory for neurotoxin-producing clostridia (botulism, tetanus), Berlin, Germany.
A case of food-borne botulism occurred in Slovakia in 2015. Clostridium botulinum type A was isolated from three nearly empty commercial hummus tubes. The product, which was sold in Slovakia and the Czech Republic, was withdrawn from the market and a warning was issued immediately through the European Commission's Rapid Alert System for Food and Feed (RASFF).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!